Abbott Will Grow Zemplar Sales With Oral Formulation, Predialysis Use
This article was originally published in The Pink Sheet Daily
Executive Summary
An NDA filing for oral Zemplar in predialysis chronic kidney disease patients is slated for this summer. Amgen's Sensipar will have "no effect" on the Zemplar I.V. business, Abbott says.